Sc. Barr et al., ACTIVITY OF LYTIC PEPTIDES AGAINST INTRACELLULAR TRYPANOSOMA-CRUZI AMASTIGOTES IN-VITRO AND PARASITEMIAS IN MICE, The Journal of parasitology, 81(6), 1995, pp. 974-978
Three oecropin-like lytic peptides (DC-1, DC-2, and DC-2R) were synthe
sized with virtually no sequence homology with the natural compound (c
ecropin B) while retaining the charge distribution, amphipathic, and h
ydrophobic properties of the natural compound. A fourth analog (alpha-
Pi) without these later properties, but a similar molecular weight, wa
s also synthesized as a nonlytic peptide control. The 3 lytic peptides
were examined for their ability to kill Trypanosoma cruzi trypomastig
otes in vitro, intracellular amastigotes in vitro, and their toxicity
to a mammalian cell line. DC-2 at 5 mu M and DC-1 and DC-2R at 10 mu M
were 100% effective in killing T. cruzi trypomastigotes in vitro, sug
gesting at least a 10-fold increase in lytic activity over previous te
sted lytic peptide analogues, SB-37 and Shiva-1. When T. cruzi-infecte
d Veto cells were treated with a single or double exposure of low conc
entrations (2.5 mu M) of DC-1, DC-2, and DC-2R there was a significant
(P < 0.05) reduction in amastigote numbers/cell when compared to untr
eated and alpha-Pi-treated T. cruzi-infected cells. Vero cells alone t
reated with the lytic peptides showed no reduction in number or toxici
ty. One of the peptides (DC-1) was tested for its toxicity in GT mice
and its ability to reduce parasitemias in T. cruzi-infected AJ mice. N
o untoward effects were seen in Al mice injected intravenously with 50
mu g/mouse daily for 10 days. There was a significant (P < 0.05) redu
ction in parasitemia and mortality by day 14 postinoculation(from 100%
to 0%) in T. cruzi-infected AJ mice given 25 mu g of DC-1/mouse on da
ys 2, 4, 6, 8, and 10 postinoculation.